Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome

Table 4 Positive blood cultures with carbapenem sensitive microorganisms within 30 days after discontinuation of EAT

	Patient (sex, age, diagnosis)	Duration of initial EAT	Micro-organism in blood culture	Days between discontinuation of EAT and positive blood culture	Focus of infection	Treatment
Period I	F 51, AML	11	Enterococcus species	4	Central venous catheter	Vancomycin, followed by amoxicillin
	F 44, AML	7	Streptococcus mitis	6	Sinusitis	Restart EAT with a carbapenem
	F 65, MDS	7	Escherichia coli	11	Urosepsis	Restart EAT with a carbapenem, followed by ceftriaxone
	M 59, AML	16	Clostridium perfringens	7	Translocation of infected trombus	Restart EAT with a carbapenem + vancomycin
Period II	M 49, AML	4	Pseudomonas aeruginosa	6	Dental focus	Piperacillin/tazobactam + tobramycin
Period II	M 42, AML	5	Enterococcus species	17	Unknown	Vancomycin

Abbreviations: F female; M male; AML acute myeloid leukaemia; MDS myelodysplastic syndrome; EAT empirical antibiotic treatment

ISSN: 2047-2994